CD36 and non-small cell lung carcinoma: Our findings highlight the clinical relevance of the metabolic-immune axis in NSCLC and propose that key BAM&IRDEGs, particularly SLC1A5 and CD36, are not only potential therapeutic targets but also promising candidates for inclusion in liquid biopsy panels.